Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $143.44.
Several brokerages have recently issued reports on PRAX. Guggenheim raised their target price on Praxis Precision Medicines from $155.00 to $170.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Wedbush lifted their price objective on Praxis Precision Medicines from $40.00 to $48.00 and gave the stock a “neutral” rating in a report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Praxis Precision Medicines in a report on Tuesday, September 10th. Oppenheimer reissued an “outperform” rating and issued a $143.00 price objective (up previously from $134.00) on shares of Praxis Precision Medicines in a report on Wednesday, September 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $145.00 price objective on shares of Praxis Precision Medicines in a report on Tuesday, September 3rd.
Get Our Latest Stock Analysis on Praxis Precision Medicines
Praxis Precision Medicines Trading Up 0.3 %
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($1.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.38) by $0.64. Praxis Precision Medicines had a negative return on equity of 61.47% and a negative net margin of 6,987.01%. The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $1.44 million. On average, sell-side analysts forecast that Praxis Precision Medicines will post -8.5 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in PRAX. RA Capital Management L.P. bought a new stake in shares of Praxis Precision Medicines during the 1st quarter valued at about $50,548,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Praxis Precision Medicines during the 1st quarter valued at about $32,707,000. Vanguard Group Inc. boosted its position in shares of Praxis Precision Medicines by 100.6% during the 1st quarter. Vanguard Group Inc. now owns 744,069 shares of the company’s stock valued at $45,403,000 after acquiring an additional 373,131 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Praxis Precision Medicines during the 1st quarter valued at about $18,878,000. Finally, Marshall Wace LLP boosted its position in shares of Praxis Precision Medicines by 105.2% during the 2nd quarter. Marshall Wace LLP now owns 248,381 shares of the company’s stock valued at $10,273,000 after acquiring an additional 127,357 shares during the last quarter. Hedge funds and other institutional investors own 67.84% of the company’s stock.
Praxis Precision Medicines Company Profile
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Further Reading
- Five stocks we like better than Praxis Precision Medicines
- Where to Find Earnings Call Transcripts
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Invest in the Best Canadian StocksĀ
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.